Cargando…
Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics
BACKGROUND: Poly (ADP)-ribose polymerase (PARP) inhibitors have entered routine clinical practice for the treatment of high-grade serous ovarian cancer (HGSOC), yet the molecular mechanisms underlying treatment response to PARP1 inhibition (PARP1i) are not fully understood. METHODS: Here, we used un...
Autores principales: | Franz, Alexandra, Coscia, Fabian, Shen, Ciyue, Charaoui, Lea, Mann, Matthias, Sander, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539835/ https://www.ncbi.nlm.nih.gov/pubmed/34686201 http://dx.doi.org/10.1186/s13048-021-00886-x |
Ejemplares similares
-
Mass spectrometry–based proteomics in cell biology
por: Walther, Tobias C., et al.
Publicado: (2010) -
Ultra‐high sensitivity mass spectrometry quantifies single‐cell proteome changes upon perturbation
por: Brunner, Andreas‐David, et al.
Publicado: (2022) -
Is mass spectrometry ready for proteome-wide protein expression analysis?
por: Rappsilber, Juri, et al.
Publicado: (2002) -
Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry
por: Isabelle, Maxim, et al.
Publicado: (2010) -
Mass spectrometry-based proteomics techniques and their application in ovarian cancer research
por: Swiatly, Agata, et al.
Publicado: (2018)